# Chinese biotech industry

Type: industry

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/chinese-biotech-industry
Canonical HTML page: https://getbiobrief.com/entity/chinese-biotech-industry

## Timeline

- **2026-06-22**: NMPA releases 2025 report — China's National Medical Products Administration publishes comprehensive statistics on the record-breaking clinical trial activity.
- **2026-02**: Cost advantages quantified — At the Outsourcing in Clinical Trials conference in California, China's trial costs were reported 50–60% lower and timelines faster than in the US.
- **2025**: Record trial count achieved — 5,215 clinical drug trials registered, more than double 2020, with 57.5% being new drug trials and cancer treatments dominating.
- **2020**: Pre-surge baseline — Approximately 2,600 clinical drug trials registered in China (implied by 2025 doubling).

## Recent coverage (1 stories)

### China’s 5,215 Clinical Trials in 2025 Double Since 2020; Cancer Drugs Lead Surge
2026-06-24 10:39:00 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

With 5,215 clinical drug trials registered in 2025, China has more than doubled its pipeline since 2020, with 57.5% focused on novel drugs and cancer treatments topping the list. The rapid expansion and 50–60% cost advantage compared to the US are reshaping the global biopharma landscape, but Washington is scrutinizing implications for drug quality and security.
Full story: https://getbiobrief.com/story/china-5215-clinical-trials-2025-oncology-lead

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.